PLX
HEALTHCAREProtalix BioTherapeutics Inc
$2.02+0.06 (+3.06%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving PLX Today?
No stock-specific AI insight has been generated for PLX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.32$3.19
$2.02
Fundamentals
Market Cap$163M
P/E Ratio—
EPS$-0.08
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding80.6M
PLX News
20 articles- Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026Yahoo Finance·May 6, 2026
- April 2026 Penny Stocks With Promising PotentialYahoo Finance·Apr 10, 2026
- Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ...Yahoo Finance·Mar 18, 2026
- PLX: 2025 Full Year ResultsYahoo Finance·Mar 18, 2026
- Protalix BioTherapeutics advances Fabry disease and gout programs during 2025Proactive Investors·Mar 18, 2026
- Protalix: Q4 Earnings SnapshotYahoo Finance·Mar 18, 2026
- Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business ResultsYahoo Finance·Mar 18, 2026
- Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026Yahoo Finance·Mar 11, 2026
- Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimenProactive Investors·Mar 9, 2026
- Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼Yahoo Finance·Mar 9, 2026
- 3 Promising Penny Stocks With Market Caps Up To $400MYahoo Finance·Feb 9, 2026
- PLX: CHMP Delivers Positive OpinionYahoo Finance·Feb 3, 2026
- Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EUYahoo Finance·Jan 30, 2026
- Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EUYahoo Finance·Jan 30, 2026
- Baozun And 2 Other Promising Penny StocksYahoo Finance·Jan 9, 2026
- Protalix BioTherapeutics Letter to StockholdersYahoo Finance·Jan 5, 2026
- PLX: Secarna’s Antisense Oligonucleotide Discovery CollaborationYahoo Finance·Dec 22, 2025
- Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option AgreementYahoo Finance·Dec 17, 2025
- PLX: Protalix Seeks Re-Examination of CHMP OpinionYahoo Finance·Nov 17, 2025
- Protalix BioTherapeutics Inc (PLX) Q3 2025 Earnings Call Highlights: Navigating Revenue ...Yahoo Finance·Nov 13, 2025
All 20 articles loaded
Price Data
Open$2.00
Previous Close$1.96
Day High$2.07
Day Low$1.95
52 Week High$3.19
52 Week Low$1.32
52-Week Range
$1.32$3.19
$2.02
Fundamentals
Market Cap$163M
P/E Ratio—
EPS$-0.08
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding80.6M
About Protalix BioTherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—